OBJECTIVES: Mechanical circulatory support (MCS) may be required after orthotopic heart transplantation (OHTx) in children for the treatment of failure or rejection. We review the incidence and outcomes of post-transplant MCS in our institution.
INTRODUCTION
Heart transplantation is now performed routinely with good outcomes in children with end-stage heart failure secondary to cardiomyopathy (CM) with failed palliation or correction of congenital heart disease (CHD) [1] . Early mortality following heart transplantation is mainly due to primary graft failure (PGF) or acute rejection (AR). A high dose of inotropic drugs, with or without mechanical circulatory support (MCS), remains the mainstay of treatment for early graft failure. Results of MCS in this group are encouraging [2] [3] [4] [5] [6] [7] . Extracorporeal membrane oxygenation (ECMO) has been the mainstay of support in these patients; however, the success of ventricular assist device (VAD) support using a Berlin Heart has added another MCS modality in managing this group. By using the two available techniques, we have undertaken a stepwise approach in managing these patients, applying them to maximize their potential in extending the time of support required for recovery or re-transplantation. This report is a retrospective analysis of our experience of MCS provided by ECMO and/or VAD in children who underwent heart transplantation and subsequently showed PGF or AR.
MATERIALS AND METHODS
The study was a retrospective chart review of all patients under the age of 16 years who underwent isolated orthotopic heart transplant (OHTx) at our institution and subsequently required MCS. MCS was classified as early or late if instituted within 30 days from the OHTx or after. The support offered was either veno-arterial (VA)-ECMO or ventricular assist with a Berlin Heart Excor (BHE) device or a Levitronix CentriMag (LTX), either as left or bi-ventricular assist device (BIVAD).
From January 2003 to January 2011, 100 children underwent isolated OHTx at our institution, and 17 episodes of MCS were required in 15 patients (15%). These patients consisted of seven males and eight females. The mean age at transplant was 7.15 ± 5.25 years, with a mean weight of 28.2 ± 17.7 kg. We divided the patients in two groups according to their primary diagnosis. Group I included patients with CM and Group II consisted of those with CHD. There were 10 patients in Group I and 5 in Group II. The distribution of diagnoses is seen in Table 1 . In Group I, 8 of 10 patients had not had previous cardiac surgery and 1 had had an aortic coarctation repaired and subsequently ballooned. The indication for heart transplant in this group was the development of severe heart failure, except in the child with total cavopulmonary connection, who developed a failing Fontan circulation. Seven patients also required MCS as a bridge to transplantation before the primary OHTx (Fig. 1) . Four patients underwent cardiac catheterization before OHTx to assess the suitability of heart transplant. The mean pulmonary artery pressure was 25 ± 10 mmHg, with the pulmonary vascular resistance found to be elevated in one patient. The common preoperative medical support consisted of inotropes (milrinone, dobutamine and adrenaline), ace-inhibitors, diuretics, sildenafil and, in specific cases (six patients), mechanical ventilatory support was also required. Heart transplant characteristics of patients are shown in Table 2 . The immunosuppression therapy was a triple therapy consisting of methylprednisolone, cyclosporine and azathioprine. Induction treatment was undertaken using basiliximab and anti-thymocyte globulin, depending on the presence of an active infection. The two main reasons for the institution of MCS after OHTx were PGF in eight patients and AR in six patients. PGF occurred soon after OHTx (mean time of early failure was 5.3 ± 7.85 days), manifesting with low cardiac output requiring increasing doses of inotropes, acidosis, poor oxygenation, end-organ failure and episodes of cardiac arrest. AR was diagnosed from clinical presentation, echocardiographic findings and/or endomyocardial biopsy showing evidence of rejection. Except in one child, all the other AR episodes were late failures, with a mean time of 9914 ± 1014 days. There were 10 support episodes for early failure (59%) and seven for late failure (41%), with two children requiring two runs of support: one child was supported for early failure on the day of transplant and then had a late failure 6.5 years after OHTx; the other child had two episodes of late failure, the first at 14 months and the second at 6 years and 9 months after OHTx. VA-ECMO was used in 12 episodes (71%), VA-ECMO was converted into VAD in 3 (17%) and VAD only was used in 2 episodes (12%). VA-ECMO was undertaken using peripheral cannulation in four supports and central cannulation in eight patients. The mean time of MCS after OHTx in VA-ECMO group was 5.1 ± 3.72 days; in VA-ECMO followed by VAD group, the duration was 7 ± 5.6 days on VA-ECMO and 34 ± 21.6 days on VAD; in the VAD only group it was 20 ± 9.9 days. While on support, patients underwent routine daily echocardiogram to establish the improvement or deterioration of cardiac function. In-hospital and outpatient records of all patients were reviewed. Data were collected retrospectively regarding hospital course and long-term survival. The follow-up was completed in all patients (100%). Variables examined were cardiac diagnosis; age and weight at the primary transplant; duration of support before surgery; timing and type of failure; duration of support after failure; characteristics of support and outcomes. In the statistical analysis, continuous variables are expressed as mean ± standard deviation.
RESULTS
The overall survival to discharge was 66%, with five in-hospital deaths, four on MCS and one 4 weeks after successful weaning from support. Seven children (46%) were successfully weaned off support with recovery of graft function, and six survived to hospital discharge. Four patients (28%) underwent cardiac re-transplantation: all survived to hospital discharge with one child dying 1 year later. Among the 10 children with early failure, eight were successfully weaned from support with recovered cardiac function, with one child dying of overwhelming sepsis 4 weeks later. One died on support and one underwent re-transplantation. In the early failure group, eight children (80%) survived to discharge, with one child subsequently developing heart failure requiring late support. All patients with early failure were supported with VA-ECMO (six centrally and four peripherally), with one boy requiring conversion to BHE-BIVAD for inadequate cardiac output and bleeding. Interestingly, all the children with CHD as primary diagnosis required MCS after OHTx due to early failure. Patients with late failure had seven runs of MCS in six children (five plus the child included in the early failure group that also developed late failure). Among these, three died while on support and three underwent re-transplantation and all survived to hospital discharge. AR was the cause of late failure in these children, all with primary diagnosis of CM. A summary of the clinical course of all patients is shown in Fig. 2 . Overall, the early failure group shows a better survival rate to discharge compared with the late failure group (78 vs 50%; P < 0.0001).
DISCUSSION
As a result of chronic donor organ shortages, several strategies have been developed in recent times to facilitate an increase in utilization of donor hearts. These include using ABOincompatible hearts [8, 9] , desensitization of human leukocyte antigen (HLA)-incompatible recipients [10, 11] and use of marginal donors [12, 13] . Inherent to these interventions is a potential for graft damage either in the early postoperative period due to haemodynamic or immunological reasons or in the late period due to chronic graft vasculopathy as a consequence of HLA-or cell-mediated rejection [14] . MCS can be utilized in the treatment of PGF so as to provide a period of haemodynamic stability to allow either the recovery of cardiac function or the institution of immunological interventions. In the late graft failure, the MCS can serve as a bridge to recovery from a rejection episode or to re-transplantation. The indication for MCS in the early graft failure in our experience was low-output state manifested by hypoxia, acidosis and renal impairment. In most of our patients, the MCS was instituted relatively late compared with other reports [2, 5, 15] . This may be due to relatively unusual occurrences of early right ventricular failure common to other reports. Our predominant mode of support has been VA-ECMO. Like others, we have traditionally used VA-ECMO as a means of support because of its immediate availability and relative familiarity with this technique. In addition, if recovery were to occur, cardiac function in PGF should improve in a time frame where VA-ECMO can be used successfully. Although PGF could be univentricular and may be amenable to univentricular support, we have opted to undertake VA-ECMO as a result of our previous experience in adult patients who, soon after institution of univentricular support required biventricular assist. In addition, ECMO allows full circulatory support with reversal of acidosis and preservation of end organ function along with the rest for both the ventricles. The mode of cannulation for VA-ECMO is dependent on multiple factors. These include the timing of the institution of support, the patency of peripheral vasculature and anatomical variations. In the past, we have strived to undertake peripheral cannulation, if possible, to avoid the reopening of chest and thus producing an additional source of bleeding. However, this policy has been tempered by the need to achieve satisfactory circulatory support. Like that of others, our policy now is to undertake central cannulation [16] . We also feel that this mode of support allows easier decompression of the left ventricle owing to satisfactory access via the left atrium. This mode of support is also useful if there are systemic venous anomalies common to patients with congenital diagnosis. A major disadvantage of this form of support is postcannulation bleeding caused by the reopening of the chest and consequently by heparanization. In selected cases, we have intentionally waited for several hours before the institution of VA-ECMO to avoid bleeding due to re-heparinization. However, our rapidly expanding experience with BHE has allowed us to utilize this mode of support in some selected cases. The use of a Berlin Heart in this group carries two advantages: firstly, better haemostasis can be achieved by reversing anticoagulation completely once the Berlin Heart has been inserted. This can avoid the perioperative bleeding on VA-ECMO which can be persistent and catastrophic due to coagulopathy and a constant need for blood products. This problem was encountered in patient number 9 (Table 2) where VA-ECMO was converted to BHE-BIVAD with the achievement of satisfactory haemostasis after 24 h of truculent bleeding, which could not be stopped in spite of desperate surgical manoeuvres. Secondly, the period of support could be prolonged beyond the remit of VA-ECMO, allowing recovery to become manifest or extending the time needed to find a suitable donor. In the two case in which we used this form of support, the cannulation was standard for a Berlin Heart. Cannulation of the pulmonary artery was undertaken by patching the pulmonary artery, thus avoiding the danger of suture line disruption. Similarly, the aortic cannula was carefully sited to avoid the aortic suture line. In one case, delayed sternal closure was undertaken after the chest was left packed with swabs for additional haemostatic control. The theoretical risk of ventriculotomy causing additional risk to recovery of the left ventricle was not seen in our patients. Patient number 9 (Table 2) , whose heart recovered on BHE from early graft failure, continues to show excellent cardiac function 2 years after the event. There have been reports of the use of a Levitronix CentriMag ® as rescue therapy for recovery for PGF in adults [17] . This (Levitronix, LLC, Waltham, MA, USA) is an extracorporeal, centrifugal VAD that uses magnetically levitated, bearingless motor technology. It can be used for univentricular or biventricular support for up to 30 days and has low haemolysis and thrombogenecity profile. We have used it as a bridge to transplantation device in several patients. However, we have not had the opportunity of using it in this group. We feel that it can have a role in patients where adequate decompression of the heart could not be achieved with the paracorporeal device. Patients with late failure group differ from the early group in one major area insofar as there is no recent sternotomy. Therefore, there are certain distinct advantages of using VADs in this group. The putative advantages of VAD over ECMO would include a longer period of support allowing anti-rejection treatment to be undertaken and having a fall back position of rescue transplantation. VADs also have the advantage that peripheral cannulation is avoided thus sparing them for later use such as cardiac biopsy required for monitoring for rejection. The cannulation for this group is relatively straightforward as no fresh suture lines are at risk. The use of VA-ECMO in post-cardiac transplant period has been well described in both adults and children [2, 5, 15, [18] [19] [20] [21] . However, the use of VADs in this setting has only been reported in the adult literature [3, 4, 22, 23] . We feel that the comparatively better result of posttransplant support in our series is related to the availability and experience with VADs. We were able to extend the period of support by combining various MCS options allowing recovery or re-transplantation to occur. In summary, early requirement for MCS post-transplant is still associated with good outcomes. Late support outcomes are less favourable but still offer 50% survival in children who would otherwise certainly die.
APPENDIX. CONFERENCE DISCUSSION
Dr G. Gerosa (Padova, Italy): Your presentation raises many issues but unfortunately I am allowed to pose only two questions. I will therefore concentrate on the selection criteria and decision-making process.
Without any doubt, as you pointed out, VAD is superior to ECMO because you can avoid peripheral cannulation, and also you can achieve a longer period of support. So my question is, can you elaborate on the criteria that you apply for selecting the mode of support, the modality of support, and in which cases you would refuse to embark on MCS?
The second question relates to the ABO incompatible heart. You presented the ABO incompatible hearts that have been supported, but in the overall pediatric population that you transplanted, how many patients received an ABO incompatible heart or a marginal donor? In other words, what was the incidence of patients requiring MCS because of early or late failure for the ABO incompatible or marginal donors?
Dr Perri: Regarding the first question, we considered the advantage of VAD as explained before, but we think there is also advantage in the use of ECMO. And we think the better strategy is a combination of different MCS options. For example, if there is acute deterioration, if we think the support is required for a short time, we put the patient on ECMO to recover the cardiac function. But if there is recovery within a short time, we converted ECMO to VAD. At the same time, we think a long period of support is necessary to start immunological therapy.
On the basis of the acute deterioration of the condition of the patient, we decide whether to use ECMO or VAD and whether a short or a long period of support is required.
Regarding the second question, in children under two years there is 15% incidence of ABO and HLA mismatch at transplant procedure. And for the marginal donor, I think there is 10%. Particularly in the UK, there is a situation when there is a shortage of good organs for the children, 1 organ for 100 children, and we are forced to perform the borderline procedure.
